A61K 9 - Medicinal preparations characterised by special physical form

Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
10/2002
10/17/2002	WO2002080967A1 Method to inhibit airway hyperresponsiveness using aerosolized t cell receptor antibodies
10/17/2002	WO2002080941A1 Compositions for preparing external carbon dioxide agents
10/17/2002	WO2002080915A2 Composition for the treatment of night sight problems (halos, coma and glare) comprising aceclidine
10/17/2002	WO2002080912A1 Reconstitutable parenteral composition containing a cox-2 inhibitor
10/17/2002	WO2002080910A1 Preparation of formulations of angiotensin ii at1 receptors antagonists for the treatment of arterial hypertension, other cardiovascular illnesses and its complications
10/17/2002	WO2002080902A1 Solid pharmaceutical composition comprising 4 -cyano-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono- m toluidide and pvp
10/17/2002	WO2002080890A2 A jasmonate pharmaceutical composition for treatment of cancer
10/17/2002	WO2002080887A2 Timed pulse release composition
10/17/2002	WO2002080885A1 Detoxification and decontamination using nanotechnology therapy
10/17/2002	WO2002080884A2 Powder inhaler formulations
10/17/2002	WO2002080883A2 Method and composition for solubilising a biologically active compound with low water solubility
10/17/2002	WO2002080881A2 Process for making protein delivery matrix and uses thereof
10/17/2002	WO2002080859A2 Inhalation drug combinations
10/17/2002	WO2002080840A2 Immunity adjuvant containing a complexed metal cation and vaccine containing same
10/17/2002	WO2002080797A1 Vessel sealing instrument
10/17/2002	WO2002080682A1 Improved anti-inflammatory herbal composition and method of use
10/17/2002	WO2002080678A1 Antifungal composition with enhanced bioavailability
10/17/2002	WO2002080668A2 Antimicrobial formulations
10/17/2002	WO2002080648A2 Mucosal boosting following parenteral priming
10/17/2002	WO2002070524A3 N-but-3-enyl norbuprenorphine and its use as analgesic
10/17/2002	WO2002067890A3 Method and product for skin lightening
10/17/2002	WO2002067677A3 Patch for the release of volatile substances to environment
10/17/2002	WO2002065991A3 Divalproex sodium tablets
10/17/2002	WO2002062260A3 Improved ophthalmic and contact lens solutions containing forms of vitamin b
10/17/2002	WO2002056861A3 Syntactic deformable foam compositions and methods for making
10/17/2002	WO2002043702A3 Pharmaceutical compositions for inhalation
10/17/2002	WO2002043701A3 Method of making particles for use in a pharmaceutical composition
10/17/2002	WO2002043699A3 Preparation of large liposomes by infusion into peg
10/17/2002	WO2002043693A3 Pharmaceutical compositions for inhalation
10/17/2002	WO2002036145A3 Kahalalide f formulation
10/17/2002	WO2002028372A3 Systemic delivery of compounds through non-invasive bladder administration
10/17/2002	WO2002019992A3 Switchable tackiness coating compositions for ophthalmic implants
10/17/2002	WO2002013785A3 Drug delivery system with burst electrode
10/17/2002	WO2002007772A3 Improved oral dosage formulations
10/17/2002	WO2001058238A9 Method and system for producing customized cosmetic and pharmaceutical formulations on demand
10/17/2002	WO2001057015A9 INTERNAL 1,15-LACTONES OF FLUPROSTENOL AND RELATED PROSTAGLANDIN F2α ANALOGS AND THEIR USE IN THE TREATMENT OF GLAUCOMA AND INTRAOCULAR HYPERTENSION
10/17/2002	WO2001041760A8 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
10/17/2002	US20020151876 Devices and methods for management of bone density
10/17/2002	US20020151875 Patient activated administration of drug bolus from implantable drug delivery system
10/17/2002	US20020151792 Method for ultrasound triggered drug delivery using hollow microbubbles with controlled fragility
10/17/2002	US20020151776 Methods and devices for sealing microchip reservoir devices
10/17/2002	US20020151683 Peptide for use in the prevention and treatment of viral diseases
10/17/2002	US20020151650 Multiblock biodegradable hydrogels for drug delivery and tissue treatment
10/17/2002	US20020151617 Biodegradable polyphosphate copolymers such as poly(L-lactide-co-ethyl phosphate)
10/17/2002	US20020151600 Administering a formulation containing a sesquiterpene alcohol, particularly cedrol, having a boiling atleast 250 degree C. to a person in need for regulation of autonomic nerve activity
10/17/2002	US20020151599 Formulations having an antiviral action
10/17/2002	US20020151598 Bronchodilating compositions and methods
10/17/2002	US20020151597 Formoterol, or a derivative; long term storage stability
10/17/2002	US20020151594 Method to treat chronic heart failure and/or elevated cholesterol levels using 3,5-diiodothyropropionic acid and method to prepare same
10/17/2002	US20020151593 Water-soluble creatine monohydrate formulations and process for their preparation
10/17/2002	US20020151589 Levodopa (l-dopa) ethyl ester, carbidopa or benserazide, a filler, a disintegrant, and a lubricant tablets used to treat Parkinson's disease
10/17/2002	US20020151562 Compositions and methods for treating allergic fungal sinusitis
10/17/2002	US20020151559 Analgesic combination of oxycodone and 6-MNA
10/17/2002	US20020151541 For treatment of respiratory tract diseases
10/17/2002	US20020151537 Calcium channel blocker agent selected from diphenylalkylamines, benzothiazepines or dihydropyridines; useful for reducing fibrosis in elastic tissue of human male penis
10/17/2002	US20020151516 Carrier:nucleic acids complexes containing nucleic acids encoding anti-angiogenic peptides and their use in gene therapy
10/17/2002	US20020151508 Administering therapeutically effective amount of liposomal anthracycline composition in association with therapeutically effective amount of antibody directed against extracellular domain of growth factor receptor
10/17/2002	US20020151474 Processes for making pharmaceutical oral ECB formulations and compositions
10/17/2002	US20020151070 Lipid compounds and compositions containing them which can be used for the transfer of at least one active substance, in particular a polynucleotide, into a target cell and use in gene therapy
10/17/2002	US20020151004 Delivery vehicles and methods for using the same
10/17/2002	US20020150638 Solid form compositions containing an extract of a raw material as the active ingredient and process of preparing the same
10/17/2002	US20020150630 Zinc chloride composition, unit dose packaging, applicator, and method of use in treating cancer and other skin diseases
10/17/2002	US20020150628 Microbiocides; viricides; anticancer agents
10/17/2002	US20020150626 Encapsulating matrix; gene therapy
10/17/2002	US20020150625 Fineness particle size; hormone replacement therapy
10/17/2002	US20020150622 Controlled release of anti-arrhythmic agents
10/17/2002	US20020150621 Sustained release of anesthetic; encapsulated matrix
10/17/2002	US20020150620 Oral itraconazole formulations and methods of making the same
10/17/2002	US20020150619 Erythromyacin antibiotic product, use and formulation thereof
10/17/2002	US20020150618 Process for preparing solid dosage forms of very low-dose drugs
10/17/2002	US20020150617 Free of excipients; compaction
10/17/2002	US20020150616 Mixture of drug with acid and polymer
10/17/2002	US20020150615 Injectable pharmaceutical composition comprising microdroplets of a camptothecin
10/17/2002	US20020150614 Effervescent base
10/17/2002	US20020150613 Adhesive mixture for transdermal delivery of highly plasticizing drugs
10/17/2002	US20020150611 Surgical seals; drug delivery; spraying, coagulation
10/17/2002	US20020150605 Drug supported by biodegradable polymer such as crosslinked hyaluronic acid
10/17/2002	US20020150603 Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products
10/17/2002	US20020150602 Thickener oil phase
10/17/2002	US20020150596 Ointment having micro bubbles containing a liquid and methods
10/17/2002	US20020150577 Transforming growth factor; transgenic animal; increas ratios of muscle mass
10/17/2002	US20020150550 Cosmetic surgery
10/17/2002	US20020150549 Sustained release
10/17/2002	US20020150544 Water soluble film for oral administration with instant wettability
10/17/2002	US20020150539 Ultrasound imaging and treatment
10/17/2002	US20020150538 Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof
10/17/2002	US20020148463 Use of intracellular calcium chelators to increase surfactant secretion in the lungs
10/17/2002	DE10155685A1 Preparation of controlled release tablets containing the calcium channel blocker nimodipine in amorphous form, useful e.g. in treating cerebral diseases, under mild temperature conditions to give good release profile
10/17/2002	DE10118306A1 Composition for intranasal administration of imidazo-triazinone derivative cGMP PDE inhibitor for treatment of erectile dysfunction, also containing local anesthetic to prevent nasal blockage and improve absorption
10/17/2002	DE10118305A1 Composition for intranasal administration of cGMP PDE inhibitor for treatment of erectile dysfunction, also containing local anesthetic to prevent nasal blockage and improve absorption
10/17/2002	DE10118160A1 Microparticles for delayed release of drugs, especially proteins or peptides, from polymer matrix, prepared by encapsulation under controlled conditions to maximize drug loading and minimize initial burst phase release
10/17/2002	DE10118146A1 Artificial respiration apparatus, for patients with a respiratory distress syndrome, has an aerosol generator at the hose system to give an effective delivery of perfluorocarbon into the patient's lungs
10/17/2002	DE10118109A1 Production of glycerol carbamate esters useful as thickeners in detergent, cosmetic and pharmaceutical compositions, comprises reacting a glycerol, diglycerol or polyglycerol carbonate with an amine
10/17/2002	DE10117049A1 New pharmaceutical composition useful for preparing solid and liquid dosage forms, e.g. ophthalmic solutions, comprises an anionic surfactant with a basic polymer or a cationic surfactant with acidic polymer, and an active ingredient
10/17/2002	DE10116197A1 New lipid-soluble methylprednisolone 21-ester derivatives, useful as antiinflammatory, immunosuppressive or antiallergic agents, especially in liposome formulations or lipid coatings on implants
10/17/2002	CA2762966A1 Hsa-free formulations of interferon-beta
10/17/2002	CA2443362A1 Stabilization and terminal sterilization of phospholipid formulations
10/17/2002	CA2443060A1 Methods and gel compositions for encapsulating living cells and organic molecules
10/17/2002	CA2443040A1 Solid pharmaceutical composition comprising 4 -cyano-trifluoro-3-(4-fluorophenyl-sulphonyl) -2-hydroxy-2-methylpropiono- m toluidide and pvp
10/17/2002	CA2442964A1 Improved anti-inflammatory herbal composition and method of use

1 ... 2222 2223 2224 2225 2226 2227 2228 2229 2230 2231 2232 2233 2234 2235 2236 2237 2238 2239 2240 2241 2242 ... 2991